Vaxneuvance (pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)) suspension for injection in pre-filled syringe: Important information regarding the potential for breakage of Vaxneuvance pre-filled syringes

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Vaxneuvance
Active substance
Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)
Therapeutic area (MeSH)
Pneumococcal Infections
Regulatory outcome
Maintenance
DHPC type
Quality defect
Human ATC code
J07AL02
Dissemination date
20/09/2023

How useful was this page?

Add your rating